- Home
- GTE vs LXEO Comparison
GTE vs LXEO Comparison
Compare GTE & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTE
- LXEO
- Stock Information
- Founded
- GTE 2003
- LXEO 2017
- Country
- GTE Canada
- LXEO United States
- Employees
- GTE N/A
- LXEO N/A
- Industry
- GTE Oil & Gas Production
- LXEO
- Sector
- GTE Energy
- LXEO
- Exchange
- GTE Nasdaq
- LXEO Nasdaq
- Market Cap
- GTE 232.6M
- LXEO 252.4M
- IPO Year
- GTE N/A
- LXEO 2023
- Fundamental
- Price
- GTE $7.40
- LXEO $5.07
- Analyst Decision
- GTE Hold
- LXEO Strong Buy
- Analyst Count
- GTE 1
- LXEO 5
- Target Price
- GTE $10.00
- LXEO $23.80
- AVG Volume (30 Days)
- GTE 372.2K
- LXEO 213.9K
- Earning Date
- GTE 02-18-2025
- LXEO 01-28-2025
- Dividend Yield
- GTE N/A
- LXEO N/A
- EPS Growth
- GTE 157.68
- LXEO N/A
- EPS
- GTE 1.43
- LXEO N/A
- Revenue
- GTE $629,503,000.00
- LXEO N/A
- Revenue This Year
- GTE $3.86
- LXEO N/A
- Revenue Next Year
- GTE $16.79
- LXEO N/A
- P/E Ratio
- GTE $5.19
- LXEO N/A
- Revenue Growth
- GTE N/A
- LXEO N/A
- 52 Week Low
- GTE $4.72
- LXEO $4.78
- 52 Week High
- GTE $10.40
- LXEO $19.50
- Technical
- Relative Strength Index (RSI)
- GTE 52.97
- LXEO 31.13
- Support Level
- GTE $7.51
- LXEO $4.78
- Resistance Level
- GTE $8.04
- LXEO $7.66
- Average True Range (ATR)
- GTE 0.38
- LXEO 0.57
- MACD
- GTE -0.00
- LXEO -0.15
- Stochastic Oscillator
- GTE 45.89
- LXEO 10.07
About GTE Gran Tierra Energy Inc.
Gran Tierra Energy Inc is an independent energy company. It is engaged in the acquisition, exploration, development, and production of oil and gas properties. The firm produces light crude oil, supplemented with medium crude and natural gas. Gran Tierra holds interests in producing and prospective properties in Colombia and prospective properties in Ecuador. The company derives its revenue from Colombia.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.